Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell?Zacks Investment Research • 07/24/26
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/23/26
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision MedicineBusiness Wire • 07/22/26
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNLBusiness Wire • 07/21/26
Cathie Wood's Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street ThinksBenzinga • 07/20/26
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology PlatformBusiness Wire • 07/20/26
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health ServiceBusiness Wire • 07/16/26
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare CancersBusiness Wire • 06/25/26
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart RhythmBusiness Wire • 06/11/26
Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome TestingBusiness Wire • 06/09/26